Form 6-K — CureVac N.V.: acquisition of Frame Cancer Therapeutics (June 8, 2022)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of June, 2022, Commission File Number 001-39446. It states that on June 8, 2022 the company issued a press release announcing its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify unique and shared neoantigens across different cancer types. The information is incorporated by reference into Form F-3, File No. 333-259613, except for statements of the Chief Executive Officer and of the Founder and Chief Executive Officer of Frame Cancer Therapeutics. The press release is Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: acquisition of Frame Cancer Therapeutics (June 8, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-06-08-0001104659-22-069328-966d3980b4/
, SHA-256 facc0f14c2ce2babb2682ae7aa798214d17c9fe6e78300d2245a379eff164e13.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On June 8, 2022, CureVac N.V. (the “Company”) issued a press release announcing the Company’s acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of the Company’s Chief Executive Officer and the statements of Frame Cancer Therapeutics’ Founder and Chief Executive Officer contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: June 8, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated June 8, 2022.
File and source
- File
- SEC_CVAC_6-K_filed2022-06-08_0001104659-22-069328.htm
- Size
- 13,421 bytes
- SHA-256
- facc0f14c2ce2babb2682ae7aa798214d17c9fe6e78300d2245a379eff164e13
- Original
- www.sec.gov